{"id":3175,"date":"2024-06-07T11:39:30","date_gmt":"2024-06-07T03:39:30","guid":{"rendered":"https:\/\/flcube.com\/?p=3175"},"modified":"2024-12-10T10:47:04","modified_gmt":"2024-12-10T02:47:04","slug":"msd-chinas-vaccine-head-tang-xiaochun-departs-hutchmed-welcomes-msds-yuan-zezhi-as-executive-vice-president","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=3175","title":{"rendered":"MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President"},"content":{"rendered":"\n

Merck, Sharp & Dohme (MSD; NYSE: MRK<\/a>) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company’s oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD’s leading anti-PD-1 therapy.<\/p>\n\n\n\n

In a leadership shuffle announced by MSD China on January 5, 2021, Tang succeeded Peng Laili as the head of the vaccine business unit, a position from which he has now departed.<\/p>\n\n\n\n

In related news, HutchMed (HKG: 0013<\/a>, NASDAQ: HCM<\/a>) has revealed that Yuan Zezhi, known as George, who was previously with MSD, joined the company on June 1, 2024, as Executive Vice-President and Head of Commercialization. Reporting directly to HutchMed\u2019s CEO Su Weiguo, Yuan brings extensive experience from his time as the head of MSD’s China medical and health business oncology division.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[1105,285,120,2675,176,1104,903],"class_list":["post-3175","post","type-post","status-publish","format-standard","hentry","category-company","tag-hkg-0013","tag-hutchmed","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nasdaq-hcm","tag-nyse-mrk"],"yoast_head":"\nMSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company's oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD's leading anti-PD-1 therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=3175\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=3175\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-07T03:39:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T02:47:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President\",\"datePublished\":\"2024-06-07T03:39:30+00:00\",\"dateModified\":\"2024-12-10T02:47:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175\"},\"wordCount\":180,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 0013\",\"HutchMed\",\"Merck\",\"Merck Sharp & Dohme\",\"MSD\",\"NASDAQ: HCM\",\"NYSE: MRK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3175#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=3175\",\"name\":\"MSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-06-07T03:39:30+00:00\",\"dateModified\":\"2024-12-10T02:47:04+00:00\",\"description\":\"Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company's oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD's leading anti-PD-1 therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3175\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3175#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President - Insight, China's Pharmaceutical Industry","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company's oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD's leading anti-PD-1 therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=3175","og_locale":"en_US","og_type":"article","og_title":"MSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=3175","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-06-07T03:39:30+00:00","article_modified_time":"2024-12-10T02:47:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=3175#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=3175"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President","datePublished":"2024-06-07T03:39:30+00:00","dateModified":"2024-12-10T02:47:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=3175"},"wordCount":180,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 0013","HutchMed","Merck","Merck Sharp & Dohme","MSD","NASDAQ: HCM","NYSE: MRK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=3175#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=3175","url":"https:\/\/flcube.com\/?p=3175","name":"MSD China's Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD's Yuan Zezhi as Executive Vice-President - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-06-07T03:39:30+00:00","dateModified":"2024-12-10T02:47:04+00:00","description":"Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that Tang Xiaochun, who served as the head of vaccine business and assistant vice-president at MSD China, has left the company. Tang initially joined MSD China in 2018 as the executive director of the company's oncology medical affairs department. During his tenure, he played a pivotal role in the successful launch of multiple indications for Keytruda, MSD's leading anti-PD-1 therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=3175#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=3175"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=3175#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD China’s Vaccine Head Tang Xiaochun Departs; HutchMed Welcomes MSD’s Yuan Zezhi as Executive Vice-President"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3175"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3175\/revisions"}],"predecessor-version":[{"id":7763,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3175\/revisions\/7763"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}